Tesofensine for Weight Loss: How This Triple Reuptake Inhibitor Stacks Up Against GLP-1s
Tesofensine is a triple monoamine reuptake inhibitor that produced ~10.6% body weight loss in Phase 2 clinical trials — through a completely different mechanism than GLP-1 agonists. Here's what the research actually shows.
💡 Quick Summary
Tesofensine is a triple monoamine reuptake inhibitor — it blocks dopamine, serotonin, and norepinephrine reuptake simultaneously. Originally developed for Parkinson's and Alzheimer's, it was rediscovered as one of the most potent weight loss agents ever tested in clinical trials. A 0.5mg daily dose produced roughly 10% body weight loss over 24 weeks. The mechanism is different from GLP-1 agonists — this works through the central nervous system, not gut hormones. Currently not approved anywhere; available as a research compound.
Tesofensine almost disappeared. It started as a neurological drug — a compound designed to treat Parkinson's disease — and washed out of that development pipeline when it didn't work well enough for that indication. Most compounds that fail Phase 2 for their primary target end up in a file somewhere, forgotten.
But during those trials, researchers noticed something unusual: people were losing weight. A lot of it. And not just the expected 2–3% you might see from a drug that causes nausea or disrupts sleep. Real, significant weight loss from a compound with a completely different mechanism than anything else in the obesity treatment space at the time.
That observation sent tesofensine through a second development arc — this time targeting obesity. What came out of that pivot is a compound with some of the most interesting (and complicated) weight loss data in the research literature.
🔑 Key Takeaways
- Tesofensine is a triple monoamine reuptake inhibitor (dopamine, serotonin, norepinephrine) — not a peptide, but frequently covered in the research compound space
- Phase 2 clinical trials showed ~10.6% body weight loss at 0.5mg over 24 weeks — roughly double the efficacy of older weight loss drugs at the time
- Primary mechanism: appetite suppression via central nervous system, plus increased energy expenditure
- Significant cardiovascular side effects (heart rate increase, blood pressure) limit clinical development
- Not FDA-approved; available as a research compound in some markets
- Compared to modern GLP-1 agonists, tesofensine produces less total weight loss but works through a fundamentally different mechanism
What Is Tesofensine?
Tesofensine (also known as NS2330) is a triple monoamine reuptake inhibitor developed originally by NeuroSearch, a Danish pharmaceutical company. "Triple reuptake inhibitor" means it simultaneously blocks the reuptake of three neurotransmitters: dopamine, serotonin, and norepinephrine.
Reuptake inhibitors work by preventing neurons from pulling neurotransmitters back in after they've been released into the synapse. Block reuptake → more of the neurotransmitter stays active in the synapse longer. You probably recognize this mechanism from antidepressants: SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) work on the same principle, just targeting fewer receptors.
Tesofensine hits all three monoamine systems at once. That's part of what makes it pharmacologically unusual — and part of what makes the weight loss effects so significant. It's also why the cardiovascular side effects are real and not dismissible.
How Tesofensine Causes Weight Loss
Multiple mechanisms are likely in play, and they layer on top of each other in ways that make tesofensine more than just a stimulant analog.
Appetite Suppression (Primary Driver)
The dopamine and norepinephrine components suppress appetite through central nervous system pathways. This is similar to how amphetamine-based weight loss drugs work (phentermine, phendimetrazine) — but tesofensine's effect is cleaner and more sustained because it works through reuptake inhibition rather than forced monoamine release. You're extending the natural signaling rather than flooding the system with a forced dump.
Serotonin reuptake inhibition adds satiety signaling from a different angle — similar to how fenfluramine worked (without the dangerous serotonin syndrome risk, based on available data). The combination of reduced hunger plus earlier satiety from meals is more powerful than either mechanism alone.
Increased Energy Expenditure
Norepinephrine activates the sympathetic nervous system — which increases heart rate, raises body temperature slightly, and increases basal metabolic rate. This is where both the weight loss benefit and the cardiovascular risk come from simultaneously. You burn more calories at rest. You also put more demand on your heart.
Animal studies on tesofensine showed increases in spontaneous locomotor activity on top of the appetite reduction — meaning test subjects moved more, not just ate less. Whether this translates meaningfully to humans in real-world conditions is unclear from the available trial data.
Dopamine's Role: Reward and Food Seeking
This is where tesofensine gets genuinely interesting from a neuroscience perspective. Dopamine isn't just a "feel-good" chemical — it's heavily involved in reward-seeking behavior, including food reward. Elevating dopamine tone doesn't just make you feel better; it appears to reduce the compulsive drive toward hyperpalatable food specifically.
Some researchers believe this is actually the primary mechanism for tesofensine's efficacy in humans — not just appetite suppression, but a reduction in food-motivated reward behavior. If true, that would explain why it seems to work even in people who don't report dramatically reduced hunger: they just stop caring as much about food.
💡 Pro Tip
Tesofensine's mechanism is fundamentally different from GLP-1 agonists like semaglutide. GLP-1s work primarily through gut hormone signaling, slowing digestion and sending satiety signals. Tesofensine works through central neurotransmitter modulation. This means they could theoretically be complementary — but combining them isn't studied and would carry significant side effect risk.
Clinical Trial Results: The Numbers
The key human trial was a randomized, double-blind, placebo-controlled Phase 2 study published in The Lancet in 2008 (Astrup et al.). 203 obese patients were randomized to placebo, 0.25mg, 0.5mg, or 1.0mg tesofensine daily for 24 weeks, combined with a mild energy-restricted diet.
The results were striking enough to generate significant attention at the time:
| Group | Mean Weight Loss | % Body Weight Lost | Responders (>5% loss) |
|---|---|---|---|
| Placebo | 2.0 kg | ~2% | ~30% |
| Tesofensine 0.25mg | 6.7 kg | ~7% | ~60% |
| Tesofensine 0.5mg | 11.3 kg | ~10.6% | ~87% |
| Tesofensine 1.0mg | 12.8 kg | ~12.8% | ~91% |
At 0.5mg, the sweet spot of efficacy versus side effects in the trial, tesofensine produced roughly 5x the weight loss of placebo. That's an unusually strong signal for a 24-week oral weight loss trial. For context: at the time, the standard-of-care obesity drugs produced 3–5% body weight loss over similar timeframes. Tesofensine's numbers were genuinely different.
But. The 1.0mg group showed a meaningful increase in heart rate — around 7–8 bpm above baseline on average — and blood pressure effects. These cardiovascular signals are what ultimately complicated further development. The 0.5mg dose showed a smaller but still present heart rate increase (~4–5 bpm). Not catastrophic, but significant enough to require careful consideration in any population with existing cardiovascular risk factors.
Tesofensine vs Semaglutide vs Tirzepatide
Direct comparison is tricky because the trials use different populations, durations, and endpoint definitions. But it's worth laying out what we know.
| Compound | Mechanism | Avg. Weight Loss | Trial Duration | Route | Approval Status |
|---|---|---|---|---|---|
| Tesofensine | Triple monoamine reuptake inhibitor | ~10.6% (0.5mg) | 24 weeks | Oral | Not approved |
| Semaglutide | GLP-1 receptor agonist | ~15% | 68 weeks | SubQ injection | FDA-approved (Wegovy) |
| Tirzepatide | Dual GIP/GLP-1 agonist | ~21% | 72 weeks | SubQ injection | FDA-approved (Zepbound) |
A few things to note about this comparison. Tesofensine's 24-week number isn't necessarily the endpoint — some evidence suggests continued weight loss beyond that window. But extrapolating from 24-week trial data to longer-term outcomes is speculative.
GLP-1 agonists produce substantially more weight loss in longer trials. They also have more cardiovascular safety data — in fact, semaglutide has cardiovascular benefit data (SUSTAIN-6 and LEADER trials showing reduced MACE events). Tesofensine's cardiovascular profile goes the other direction. That's a significant difference when you're thinking about long-term use.
Where tesofensine has an edge: oral dosing. No injections. And potentially a different mechanism that could help people who don't respond well to GLP-1s or can't tolerate the GI side effects. The dopamine-reward mechanism specifically might be beneficial for people with binge eating patterns or strong food reward responses.
If you're considering a well-studied, clinically validated option with proven safety and strong efficacy, semaglutide from Ascension Peptides (S-5) is a more evidence-backed starting point for most people. The data on tesofensine is genuinely interesting, but it's thinner and the cardiovascular concerns are real.
Typical Research Protocol & Dosing
Based on the Phase 2 trial data, the 0.5mg dose is generally considered the research reference point — it showed the best efficacy-to-side-effect ratio in the Lancet trial. The 1.0mg dose got slightly better weight loss but with meaningfully more cardiovascular stress.
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Conservative start | 0.25mg | Once daily | Weeks 1–4 | Assess tolerability; monitor heart rate |
| Standard protocol | 0.5mg | Once daily | Weeks 5–24 | Clinical trial reference dose |
| Higher dose (research) | 1.0mg | Once daily | Variable | Significantly more cardiovascular effects; not recommended without monitoring |
Timing: typically taken in the morning, given the stimulant-adjacent effects on norepinephrine. Taking it too late in the day may affect sleep for some people — though tesofensine's effect on sleep is less studied than its effects on weight.
💡 Note
In the Lancet trial, tesofensine was combined with a mild diet intervention (~300 kcal/day deficit). Whether it's as effective in ad libitum conditions without dietary restriction is less clear. The combination of reduced appetite plus modest caloric restriction likely contributed to the results seen.
Side Effects & Safety Profile
Tesofensine's side effect profile differs meaningfully from GLP-1 agonists. Worth knowing before forming an opinion about whether it's appropriate for a given research context.
Cardiovascular
- Heart rate increase: 4–8 bpm average increase dose-dependently. This isn't trivial — sustained elevated resting heart rate has long-term implications
- Blood pressure: Modest increases in some participants at higher doses
- Palpitations: Reported by some participants in the 0.5–1.0mg range
CNS / Psychological
- Dry mouth: Commonly reported — related to sympathomimetic effects
- Insomnia: Especially at higher doses or with evening dosing
- Mood effects: Given the dopamine/serotonin component, mood changes are possible — some positive, some not. One study in Parkinson's patients noted euphoric effects, which is relevant to abuse potential considerations
- Headache: Particularly in early days of use
GI
- Nausea: Less common than with GLP-1 agonists but reported
- Dry mouth reducing appetite for liquids (see above)
Abuse Potential?
This is a legitimate research question. Triple monoamine reuptake inhibitors operate on neurotransmitter systems implicated in addiction. The theoretical concern is that dopaminergic effects could create dependence or reinforcement. Limited data from tesofensine trials didn't show clear abuse signals, but the question isn't fully answered by a 24-week Phase 2 trial. Something to be aware of.
Where to Get Tesofensine
Tesofensine has not received approval from the FDA, EMA, or most major regulatory bodies. It's not available as a pharmaceutical product in most countries.
In some jurisdictions — notably parts of Latin America — it has received approval at compounding pharmacies under various trade names. Mexico, in particular, has been a source for compounded tesofensine products.
For research purposes, tesofensine is available from some peptide/research compound suppliers. The supply chain is less standardized than for GLP-1 compounds, and quality verification (third-party testing, COAs) is more variable. If sourcing for research, mass spectrometry confirmation of identity and purity is particularly important given the narrower therapeutic window and cardiovascular implications of overdosing.
Worth considering: if the goal is research into central nervous system mechanisms of weight loss, tesofensine is genuinely interesting. If the goal is simply effective weight loss with a well-characterized safety profile, the GLP-1 class — particularly semaglutide — has a substantially stronger evidence base. Ascension Peptides carries semaglutide (S-5) as a research compound with consistent quality and availability.
For a broader look at the weight loss peptide space, see our complete guide to peptide therapy for weight loss.